FDA
-
-
-
-
-
-
-
BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
-
-
-
-
-
-
-
BioCryst completes $700 million Astria acquisition
-
-
-
-
-
-
-
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
-
-
-
-
-
-
-
RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
-
-
-
-
-
-
-
BioCryst (BCRX) names Babar Ghias as CFO and head of corporate development
-
-
-
-
-
-
-
BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries
-
-
-
-
-
-
-
BioCryst Pharma (BCRX) PT Raised to $13 at RBC Capital; 'Strong Out of the Gate in 2025'
-
328,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

